Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus
- PMID: 28939716
- PMCID: PMC5634309
- DOI: 10.1161/JAHA.117.006745
Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus
Abstract
Background: Apparent treatment resistant hypertension (aTRH) is highly prevalent in patients with type 2 diabetes mellitus (T2D) and entails worse cardiovascular prognosis. The impact of aTRH and long-term achievement of recommended blood pressure (BP) values on renal outcome remains largely unknown. We assessed the role of aTRH and BP on the development of chronic kidney disease in patients with T2D and hypertension in real-life clinical practice.
Methods and results: Clinical records from a total of 29 923 patients with T2D and hypertension, with normal baseline estimated glomerular filtration rate and regular visits during a 4-year follow-up, were retrieved and analyzed. The association between time-updated BP control (ie, 75% of visits with BP <140/90 mm Hg) and the occurrence of estimated glomerular filtration rate <60 and/or a reduction ≥30% from baseline was assessed. At baseline, 17% of patients had aTRH. Over the 4-year follow-up, 19% developed low estimated glomerular filtration rate and 12% an estimated glomerular filtration rate reduction ≥30% from baseline. Patients with aTRH showed an increased risk of developing both renal outcomes (adjusted odds ratio, 1.31 and 1.43; P<0.001 respectively), as compared with those with non-aTRH. No association was found between BP control and renal outcomes in non-aTRH, whereas in aTRH, BP control was associated with a 30% (P=0.036) greater risk of developing the renal end points.
Conclusions: ATRH entails a worse renal prognosis in T2D with hypertension. BP control is not associated with a more-favorable renal outcome in aTRH. The relationship between time-updated BP and renal function seems to be J-shaped, with optimal systolic BP values between 120 and 140 mm Hg.
Keywords: albuminuria; blood pressure; chronic kidney disease; diabetes (kidney); glomerular filtration rate; resistant hypertension.
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Figures






Similar articles
-
Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes.Kidney Blood Press Res. 2018;43(2):422-438. doi: 10.1159/000488255. Epub 2018 Mar 16. Kidney Blood Press Res. 2018. PMID: 29698970
-
Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes.J Hypertens. 2016 Oct;34(10):2090-8. doi: 10.1097/HJH.0000000000001045. J Hypertens. 2016. PMID: 27457667
-
Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes.J Diabetes Complications. 2017 Feb;31(2):419-426. doi: 10.1016/j.jdiacomp.2016.10.030. Epub 2016 Oct 29. J Diabetes Complications. 2017. PMID: 27884661
-
Hypertension in Chronic Kidney Disease.Adv Exp Med Biol. 2017;956:307-325. doi: 10.1007/5584_2016_84. Adv Exp Med Biol. 2017. PMID: 27873228 Review.
-
Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome?Adv Chronic Kidney Dis. 2014 Nov;21(6):489-99. doi: 10.1053/j.ackd.2014.08.006. Epub 2014 Oct 24. Adv Chronic Kidney Dis. 2014. PMID: 25443574 Review.
Cited by
-
Antihypertensive treatment and renal protection: Is there a J-curve relationship?J Clin Hypertens (Greenwich). 2018 Nov;20(11):1560-1574. doi: 10.1111/jch.13396. Epub 2018 Sep 28. J Clin Hypertens (Greenwich). 2018. PMID: 30267461 Free PMC article. Review.
-
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.Am J Hypertens. 2020 Dec 31;33(12):1092-1101. doi: 10.1093/ajh/hpaa073. Am J Hypertens. 2020. PMID: 32369546 Free PMC article.
-
A Study on Associations of Long Noncoding RNA HOTAIR Polymorphisms With Genetic Susceptibility to Chronic Kidney Disease.J Clin Lab Anal. 2024 Jun;38(11-12):e25086. doi: 10.1002/jcla.25086. Epub 2024 Jul 3. J Clin Lab Anal. 2024. PMID: 38958113 Free PMC article.
-
Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy.J Diabetes Res. 2022 Aug 4;2022:7787732. doi: 10.1155/2022/7787732. eCollection 2022. J Diabetes Res. 2022. PMID: 35967126 Free PMC article. Review.
-
Association of blood pressure and long-term change with chronic kidney disease risk among Chinese adults with different glucose metabolism according to the 2017 ACC/AHA guidelines.J Clin Hypertens (Greenwich). 2021 Dec;23(12):2080-2088. doi: 10.1111/jch.14371. Epub 2021 Nov 12. J Clin Hypertens (Greenwich). 2021. PMID: 34773360 Free PMC article.
References
-
- Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52:1749–1757. - PubMed
-
- Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee . Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510–e526. - PubMed
-
- De Nicola L, Gabbai FB, Agarwal R, Chiodini P, Borrelli S, Bellizzi V, Nappi F, Conte G, Minutolo R. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61:2461–2467. - PubMed
-
- Wolley MJ, Stowasser M. Resistant hypertension and chronic kidney disease: a dangerous liaison. Curr Hypertens Rep. 2016;18:36. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical